Advertisement · 728 × 90
#
Hashtag
#trelegy
Advertisement · 728 × 90
Have your or someone you know paid a high price for: Trelegy 
Image of an inhaler
Generic: none
Therapy Class: Antiasthmatic & bronchodilator
Consider sharing your story with the Oregon Prescription Drug Affordability Board

Have your or someone you know paid a high price for: Trelegy Image of an inhaler Generic: none Therapy Class: Antiasthmatic & bronchodilator Consider sharing your story with the Oregon Prescription Drug Affordability Board

Have you or someone you know paid a high price for #Trelegy?

The Oregon Prescription Drug Affordability Board (#PDAB)is reviewing high-cost drugs, like Trelegy, that may strain #Oregon patients & they need to hear from YOU!

Submit comment here: dfr.oregon.gov/pdab/Pages/p...
#OCAP #HealthPolicy

0 0 0 0
The Oregon Prescription Drug Affordability Board (PDAB) is reviewing high-cost drugs that may strain Oregon patients or our health care system. They want to hear your experience with high costs on ANY of the prescription drugs on their review list. Use the website below to share: bit.ly/or-pdab-comment

The Oregon Prescription Drug Affordability Board (PDAB) is reviewing high-cost drugs that may strain Oregon patients or our health care system. They want to hear your experience with high costs on ANY of the prescription drugs on their review list. Use the website below to share: bit.ly/or-pdab-comment

On August 20, 
the Oregon PDAB will review: Trelegy* (Fluticasone furoate; Umeclidinum bromide; Vilanterol trifenatate)
Eliquis* (Apixaban)
Xarelto (Rivaroxaban)
Cosentyx (Secukinumab)
Creon (Pancrelipase [Amylase; Lipase; Protease])
* = No generic currently avaiable

On August 20, the Oregon PDAB will review: Trelegy* (Fluticasone furoate; Umeclidinum bromide; Vilanterol trifenatate) Eliquis* (Apixaban) Xarelto (Rivaroxaban) Cosentyx (Secukinumab) Creon (Pancrelipase [Amylase; Lipase; Protease]) * = No generic currently avaiable

PDAB Has Already Reviewed:
Vraylar* (Cariprazine HCl )
Entresto (Sacubitril; Valsartan)
Ajovy (Fremanezumab-vfrm)
Emgality (Galcanezumab-gnlm)
Nurtec (Rimegepant/ rimegepant sulfate)
Ubrelvy* (Ubrogepant)
*=no generic currently available

you can still share your story about these drugs until November 19

PDAB Has Already Reviewed: Vraylar* (Cariprazine HCl ) Entresto (Sacubitril; Valsartan) Ajovy (Fremanezumab-vfrm) Emgality (Galcanezumab-gnlm) Nurtec (Rimegepant/ rimegepant sulfate) Ubrelvy* (Ubrogepant) *=no generic currently available you can still share your story about these drugs until November 19

The #Oregon #PDAB is meeting to review: #Trelegy, #Eliquis, #Xarelto, #Cosentyx, & #Creon on Aug. 20 at 8 am!

If you or someone you know has taken any of these (or any others on their list), they need to hear from you! Send a letter/sign up to speak at bit.ly/or-pdab-comment

1 0 1 0
Preview
Respiratory Weekly News – 25th April 2025 Lung & Respiratory Breakthroughs: Trelegy Data, EGPA Drug Status, Brensocatib Results & More  In this week’s roundup, we’re diving into […] The post Respiratory Weekly News – 25th April 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Respiratory Weekly News – 25th April 2025 #News #Bronchiectasis #trelegy #COPD #Asthma Comment below!

0 0 0 0
Preview
Respiratory Weekly News – 25th April 2025 Lung & Respiratory Breakthroughs: Trelegy Data, EGPA Drug Status, Brensocatib Results & More  In this week’s roundup, we’re diving into […] The post Respiratory Weekly News – 25th April 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Respiratory Weekly News – 25th April 2025 #News #Bronchiectasis #trelegy #COPD #Asthma Comment below!

0 0 0 0
Preview
Respiratory Weekly News – 25th April 2025 Lung & Respiratory Breakthroughs: Trelegy Data, EGPA Drug Status, Brensocatib Results & More  In this week’s roundup, we’re diving into […] The post Respiratory Weekly News – 25th April 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Respiratory Weekly News – 25th April 2025 #News #Bronchiectasis #trelegy #COPD #Asthma Comment below!

0 0 0 0
Preview
Theravance Biopharma Reports Exceptional Financial Growth for Q4 and Full Year 2024 Theravance Biopharma achieved record financial results for Q4 and FY 2024, with significant sales growth driven by YUPELRI® and TRELEGY milestones.

Theravance Biopharma Reports Exceptional Financial Growth for Q4 and Full Year 2024 #Ireland #Dublin #Theravance_Biopharma #YUPELRI #TRELEGY

0 0 0 0